This is not the latest version of this item. The latest version can be found here.
Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics
Name
nihms-1680998.pdf
Description
Accepted version
Size
1.1 MB
Format
Unknown
Checksum (MD5)
abd6e2becfe9aee630218743c3f109d0
Author(s)
Coffey, Jacob William
Gaiha, Gaurav Das
Traverso, Giovanni
Date Issued
January 2021
Journal
Annual Review of Pharmacology and Toxicology
Publisher
Annual Reviews
Citation
Coffey, Jacob William, Gaiha, Gaurav Das and Traverso, Giovanni. 2021. "Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics." Annual Review of Pharmacology and Toxicology, 61 (1).
Version
Author's final manuscript
Abstract
Oral vaccination enables pain-free and self-administrable vaccine delivery for rapid mass vaccination during pandemic outbreaks. Furthermore, it elicits systemic and mucosal immune responses. This protects against infection at mucosal surfaces, which may further enhance protection and minimize the spread of disease. The gastrointestinal (GI) tract presents a number of prospective mucosal inductive sites for vaccine targeting, including the oral cavity, stomach, and small intestine. However, currently available oral vaccines are effectively limited to live-attenuated and inactivated vaccines against enteric diseases. The GI tract poses a number of challenges,including degradative processes that digest biologics and mucosal barriers that limit their absorption. This review summarizes the approaches currently under development and future opportunities for oral vaccine delivery to established (intestinal) and relatively new (oral cavity, stomach) mucosal targets. Special consideration is given to recent advances in oral biologic delivery that offer promise as future platforms for the administration of oral vaccines.
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
http://dx.doi.org/10.1146/ANNUREV-PHARMTOX-030320-092348
